BUFFALO, N.Y., Nov. 26, 2018 /PRNewswire/ -- Tactiva Therapeutics, Inc. announced it has licensed new intellectual property from the Roswell Park Cancer Institute Corporation that covers the use of the Oncolytic Vaccinia Virus (OVV) armed with a CXCR4 antibody.
Pre-clinical results recently published in the Journal of Immunology (August 2018) demonstrate a potent therapeutic response with an ability to control metastatic growth and reverse the immunosuppressive tumor microenvironment. Through strong inhibition of cancer initiating cells (CIC's) and a myriad of other immuno-suppressive forces in the tumor micro-environment, there was improved tumor free survival when compared to oncolysis alone in a xenograft model.
"We are very excited to add this asset to our portfolio of intellectual property. We feel that the broad anti-tumor activity demonstrated in pre-clinical models offers tremendous hope for those suffering from ovarian cancer. CXCR4 antagonist armed viral oncotherapy may one day be a valuable component in the eradication of this highly lethal disease. The program will mesh nicely with our current efforts utilizing our DEACT (Dual Enhanced Adoptive Cell Therapy ) platform incorporating an engineered T cell and stem cell approach to improve upon current forms of TCR therapy in the treatment of solid tumors, including ovarian cancer," stated Matt Colpoys, CEO.
Tactiva plans to enter the clinic with its DEACT program in 2019. The Company is on track to initiate a basket trial in multiple solid tumor types and another in Multiple Myeloma.
About Tactiva TherapeuticsTactiva is a development stage immuno-oncology company with a unique approach to adoptive T-cell therapy. Tactiva's dual enhanced adoptive cell therapy (DEACT™) platform, consists of engineered CD4/CD8 cells which generate a durable supply of CD4 cells with direct anti-tumor activity as well as sustained helper function to CD8 T cell derived TCR-transduced effector T cells.
IR Contact: Stephanie Carrington[email protected]
Advertisement
Pre-clinical results recently published in the Journal of Immunology (August 2018) demonstrate a potent therapeutic response with an ability to control metastatic growth and reverse the immunosuppressive tumor microenvironment. Through strong inhibition of cancer initiating cells (CIC's) and a myriad of other immuno-suppressive forces in the tumor micro-environment, there was improved tumor free survival when compared to oncolysis alone in a xenograft model.
Advertisement
"We are very excited to add this asset to our portfolio of intellectual property. We feel that the broad anti-tumor activity demonstrated in pre-clinical models offers tremendous hope for those suffering from ovarian cancer. CXCR4 antagonist armed viral oncotherapy may one day be a valuable component in the eradication of this highly lethal disease. The program will mesh nicely with our current efforts utilizing our DEACT (Dual Enhanced Adoptive Cell Therapy ) platform incorporating an engineered T cell and stem cell approach to improve upon current forms of TCR therapy in the treatment of solid tumors, including ovarian cancer," stated Matt Colpoys, CEO.
Tactiva plans to enter the clinic with its DEACT program in 2019. The Company is on track to initiate a basket trial in multiple solid tumor types and another in Multiple Myeloma.
About Tactiva TherapeuticsTactiva is a development stage immuno-oncology company with a unique approach to adoptive T-cell therapy. Tactiva's dual enhanced adoptive cell therapy (DEACT™) platform, consists of engineered CD4/CD8 cells which generate a durable supply of CD4 cells with direct anti-tumor activity as well as sustained helper function to CD8 T cell derived TCR-transduced effector T cells.
IR Contact: Stephanie Carrington[email protected]
View original content:http://www.prnewswire.com/news-releases/tactiva-therapeutics-announces-license-to-oncolytic-vaccinia-virus-armed-with-cxcr4-antagonist-for-treatment-of-ovarian-cancer-300754979.html
SOURCE Tactiva Therapeutics
